U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...
As weight loss market rival Novo Nordisk drew headlines for starting a bidding war over a potential $9bn acquisition of ...
Eli Lilly partners with Walmart to sell its weight-loss drug Zepbound nationwide, giving patients easier, insurance-free access through LillyDirect.
Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...
Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.
Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback